Developing novel ADC

immuno-therapeutics to

treat high need cancers

Our lead program is ETx-22, a Nectin-4-targeting ADC – developed to bring superior efficacy to patients and with potential across a range of hard-to-treat cancers.

ETx-22 uses an innovative linker and payload technology to deliver higher efficacy, lower risk of off-target side effects and ability to avoid tumor resistance.

It is based on an antibody with unique properties designed to lower on-target side effects.

About Us

Read More >

Science

Read More >

Execution

Read More >

Partners

Read More >

Latest News

07/12/2021

Emergence Therapeutics raises €87 million Series A financing to advance Nectin-4 ADC

Series A round led by Pontifax and includes new and existing investors Lead product is a next-generation Nectin-4 ADC designed to increase efficacy and minimize toxicity Strategy is to become a dominant ADC developer   Duisburg, Germany, 7 December 2021. Emergence Therapeutics AG, a biopharmaceutical company developing novel antibody drug conjugates (ADC) for the treatment...

View Article >
05/10/2021

Emergence Therapeutics and Mablink Bioscience Enter into a Licensing Agreement to Develop Antibody Drug Conjugate as a potential cancer therapy

Emergence Therapeutics obtains the rights to develop a novel antibody-drug conjugate using Mablink Bioscience’s proprietary PSARlink™ drug-linker technology. Duisburg, Germany, and Lyon, France, 5 October 2021. Emergence Therapeutics AG, a European biopharmaceutical company developing novel antibody drug conjugate (ADC) immuno-therapeutics to treat cancers with high unmet needs and Mablink Bioscience S.A.S. a biotechnology company developing...

View Article >
25/11/2020

Emergence Therapeutics Announces Bumped-up Follow-on Seed Round Financing

Financing enables company to embark on additional targets and expand ADC technology reach Duisburg, Germany – Marseille, France, 25 November 2020: Emergence Therapeutics AG, a European biopharmaceutical company developing novel antibody drug conjugate (ADC) immuno-therapeutics to treat high need cancers, announces that is has closed a Bumped-up Follow-on Seed Round Financing from a syndicate of...

View Article >